Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer

NCT07714382 — Completed, 100 participants, Sohag University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Survival Outcomes of Residual Disease in Patients With Triple-Negative Breast Cancer Following Neoadjuvant Therapy: A Retrospective Cohort Study

Registry	NCT07714382, acronym ReS-TNBC
Status	Completed
Study type	Observational
Enrollment	100 (Actual)
Sponsor	Sohag University (Other)
Conditions	Triple-Negative Breast Cancer (TNBC)
Interventions	Chemo-radiotherapy alone, Not applicable- observational study (Procedure, other)
Dates	start 2026-05-01, primary completion 2026-06-01, completion 2026-07-01, first posted 2026-07-20, last updated 2026-07-20
Locations	1 site in Egypt

-Summary

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival

Expand all sections · Collapse all

+Arms and interventions

Chemo-radiotherapy alone (Procedure): Chemo and radiotherapy before surgery
Not applicable- observational study (Other): Not applicable. This is a retrospective observational cohort study. No study intervention is administered. Data will be collected retrospectively from patients' medical records, and all treatments were provided as part of routine clinical care.

+Outcome measures

Primary outcomes

Disease free survival [Up to 3 years]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR).

Complete clinical, pathological, treatment, and follow-up data available in the medical records.

Exclusion Criteria:

* Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery.

Patients with incomplete or missing essential clinical, pathological, or follow-up data.

Patients with a history of another primary malignancy that could affect survival analysis.

+Locations (1)

Facility	City	Country	Status
Sohag university	Sohag	Egypt